Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
about
Pharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewIs aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trialsDeterminants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.Drugs for chronic obstructive pulmonary diseaseA Belgian survey on the diagnosis of asthma-COPD overlap syndrome.Clinical implications of blood eosinophil count in patients with non-asthma-COPD overlap syndrome COPD.When is dual bronchodilation indicated in COPD?Fluticasone propionate/formoterol for COPD management: a randomized controlled trial.Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD.Reply to Correspondence Letter Regarding "Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial".Correspondence Letter Regarding "Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial".Morning symptoms in COPD: a treatable yet often overlooked factor.Stability of Blood Eosinophil Count in Patients with COPD in the UK Clinical Practice Research Datalink.The clinical profile of benralizumab in the management of severe eosinophilic asthma.Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease.Optimizing bronchodilation in the prevention of COPD exacerbationsMaintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.Comparison of the peripheral blood eosinophil count using near-patient testing and standard automated laboratory measurement in healthy, asthmatic and COPD subjects.Allergy and Chronic Obstructive Pulmonary Disease.Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma.A machine learning approach to triaging patients with chronic obstructive pulmonary disease.Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease.Recommendations for the pharmacological treatment of COPD: questions and answers.Inhaled therapies in patients with moderate COPD in clinical practice: current thinking.Blood Leukocyte Concentrations, FEV1 Decline, and Airflow Limitation. A 15-Year Longitudinal Study of World Trade Center-exposed Firefighters.Individualizing the selection of long-acting bronchodilator therapy for patients with COPD: considerations in primary care.Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study.Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease. Blood Eosinophils Gain Momentum.Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts.Triple Therapy in COPD: What We Know and What We Don't.Should Patients Switched from D to B in the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids?Update in Chronic Obstructive Pulmonary Disease 2016.The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world.Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease.
P2860
Q28070274-F578379E-8B52-4FE8-B8EC-CD15D450D11AQ30365242-6EAAB4B7-41DA-4693-A496-269BB5266A88Q33713847-A4381B4D-BF4A-4139-8029-87074FEA06B3Q33854276-791E9252-3FE0-4A61-B5ED-042DD135E1F6Q36302882-300F0CDE-213B-4CA2-AC51-E96D7D95F0A0Q37647174-B7F6B1F4-306D-4CC2-AF22-C02526E328EEQ37649862-40F0B3AF-FAF7-453E-91AD-B1CB61E5D3DDQ38598991-CBBBE9E8-1486-4318-A898-D3541F36236CQ38641441-55DB4806-5BC6-43CE-8CA6-AF1EB6838A32Q38663441-F3A4400A-7773-4494-904D-E27112AF3507Q38685218-6AD2C76E-DF20-462C-A44F-C52465F0F9EBQ38708919-979472CB-4A8C-4D31-AED2-AAFADCDE7CE5Q38708939-F3ADCAF1-F4A1-45DD-9DCB-FE1F4AC6B68DQ38747579-317E0704-A0E9-4607-83B9-63074AB30593Q38751378-75B07EBC-3B9C-48D3-80D9-F8DBFAAECC31Q38822826-CC1B1ED9-B7ED-4118-8A00-35EC80CFC8D5Q38901257-BF37ACB2-DEE9-4CDC-BBAD-D055ED2CB5A9Q39386571-5907ABD9-6ECA-4C07-BAF8-AD5A8A514891Q39426952-5C1FFE82-FA9D-45C1-B592-5B51F219FBA8Q40598255-49DF472E-9331-42EC-9922-8EE9A2F950A1Q41054096-9CCF3F57-2177-473A-9549-C4FBD8A176D0Q42280463-90A62D77-8A5B-41AE-ABF0-F5976F74CEDDQ42354353-175FA291-4CA8-4F4C-B0C8-37D55BE80A74Q42358548-4EA45424-94EE-47EB-A240-C2B5D02E67DDQ45943672-FD5C25E3-12DB-4F01-A1C0-5B2077F78B9EQ46434748-3C17F301-C4AC-413B-B491-5C703A933535Q47138049-679FA23C-D920-4E8D-9D51-576EDE010663Q47272746-1EBE4F5A-EE9F-462A-BA41-DFE4EE18D5DCQ47661714-C13014EC-1F3C-4909-AA44-402461C3E099Q47666470-E3B725AB-C323-4C51-BAC6-C887E8E9242EQ47710084-24E9F769-7E5E-470B-A2B7-89279B9C2370Q47718704-7F360F2F-C912-45BC-AE8C-4C7AE3350B20Q47724396-74AD99C7-12F5-45BF-8504-C8D643A37F10Q48089821-19125399-A8F9-49BE-ADFE-0AA75641D4D1Q48272082-85DD9A09-C1D1-4206-9616-B20027A40B55Q48335044-34F96CED-CC39-4D29-A916-22D9176A71BBQ48343193-7FEFAD53-F44C-452E-B797-63C1F2C996B8Q48343913-E23ED538-791F-4486-B5A9-568E3A5ECD39Q49281529-9F59632C-6600-428B-AA0C-0BF8FAEEA9CDQ49751199-CE0226DD-9096-48BB-B121-D2DB778A807E
P2860
Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Blood eosinophil count and exa ...... analysis of the WISDOM trial.
@en
Blood eosinophil count and exa ...... analysis of the WISDOM trial.
@nl
type
label
Blood eosinophil count and exa ...... analysis of the WISDOM trial.
@en
Blood eosinophil count and exa ...... analysis of the WISDOM trial.
@nl
prefLabel
Blood eosinophil count and exa ...... analysis of the WISDOM trial.
@en
Blood eosinophil count and exa ...... analysis of the WISDOM trial.
@nl
P2093
P50
P1476
Blood eosinophil count and exa ...... analysis of the WISDOM trial.
@en
P2093
Anne Kirsten
Bernd Disse
Helen Finnigan
Helgo Magnussen
Henrik Watz
Kay Tetzlaff
Pascal Chanez
Peter M A Calverley
Roberto Rodriguez-Roisin
Ronald Dahl
P304
P356
10.1016/S2213-2600(16)00100-4
P577
2016-04-07T00:00:00Z